Q-omics provides the consensus-scored PSMB5 profile across patient tissues and cancer cell-line models. PSMB5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PSMB5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, PSMB5 RNA expression shows 18,774 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, COAD, and ACC as cancer lineages where PSMB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMB5 survival associations across molecular data types. PSMB5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMB5 RNA expression–survival associations across cancer types. High PSMB5 expression shows unfavorable associations in HNSC, UVM, BLCA, LIHC, ACC and KICH. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PSMB5 RNA expression.
This table summarizes PSMB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMB5 shows higher tumor expression in COAD, HNSC, BLCA, LIHC, LUAD and LUSC. The COAD box plot shows higher PSMB5 RNA expression in tumor versus normal tissue (log2 FC = +1.056, t-test p < 0.001).
This table shows molecular features associated with PSMB5 in patient tissues and cancer cell lines. In patient samples, PSMB5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
